Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Common Equity: 2020-2022

Historic Common Equity for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2022 value amounting to $535.0 million.

  • Cullinan Therapeutics' Common Equity fell 20.01% to $468.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $468.8 million, marking a year-over-year decrease of 20.01%. This contributed to the annual value of $535.0 million for FY2022, which is 25.78% up from last year.
  • Per Cullinan Therapeutics' latest filing, its Common Equity stood at $535.0 million for FY2022, which was up 25.78% from $425.4 million recorded in FY2021.
  • Cullinan Therapeutics' 5-year Common Equity high stood at $535.0 million for FY2022, and its period low was $200.3 million during FY2020.
  • Its 3-year average for Common Equity is $386.9 million, with a median of $425.4 million in 2021.
  • Data for Cullinan Therapeutics' Common Equity shows a peak YoY spiked of 112.35% (in 2021) over the last 5 years.
  • Yearly analysis of 3 years shows Cullinan Therapeutics' Common Equity stood at $200.3 million in 2020, then soared by 112.35% to $425.4 million in 2021, then rose by 25.78% to $535.0 million in 2022.